COG STIM 2: Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

Sponsor
Centre Francois Baclesse (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06027632
Collaborator
UNICANCER (Other)
300
16
2
66
18.8
0.3

Study Details

Study Description

Brief Summary

Investigator propose the first French randomized comparative study to assess the efficacy of a remotely supervised online cognitive stimulation program, compared to an unsupervised online cognitive exercise intervention, in reducing cognitive complaints in localized breast cancer patients after adjuvant chemotherapy. Previous randomized studies have confirmed the effectiveness of online cognitive stimulation programs compared to standard care. The study seeks to determine the added value of remote supervision by a neuropsychologist. The control group will have access to the same online cognitive exercises as the experimental group but without supervision. Investigator has chosen not to include a wait-list group as it would be unethical to deny patients with cognitive complaints the opportunity to participate in an intervention expected to benefit them. The secondary objective is to evaluate the benefit of the supervised digitalized cognitive intervention on objective cognitive impairment.

The research hypothesis is that incorporating personalized remote support with supervision from a neuropsychologist into a digitalized cognitive stimulation program will reinforce the effectiveness of the intervention on cognitive complaints. This will be achieved by improving participation/adherence to the online cognitive stimulation program, as well as through the personalized supervision itself. Investigator believe that the supervision sessions, including educational components, will enable patients to identify their strengths, promote their cognitive awareness, and develop individualized strategies to apply their compensatory abilities in real-life situations. Since cognitive difficulties have multiple underlying causes, reducing these symptoms requires a multifaceted approach. The hypothesis is that combining cognitive training (which increases neuroplasticity and directly targets the cognitive domains affected by cancer and its treatments), with structured supervised educational sessions based on compensatory strategies, will yield better outcomes than online cognitive stimulation alone.

Condition or Disease Intervention/Treatment Phase
  • Other: Cognitive exercises with supervision
  • Other: Cognitive exercises without supervision
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer: a Multicenter Randomized Controlled Trial
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2028
Anticipated Study Completion Date :
Mar 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Other: Remotely-supervised online cognitive stimulation intervention

Other: Cognitive exercises with supervision
The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the "PRESCO" program of the "HAPPYNeuron-Pro" software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed

Other: Open access to online home-based cognitive exercises without supervision

Other: Cognitive exercises without supervision
Patient will have access to the program named "PRESCO" of the "HAPPYNeuron-Pro" software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed

Outcome Measures

Primary Outcome Measures

  1. Average change in the score of the Perceived Cognitive Impairment (PCI) subscale score of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) [After 12 weeks]

    Perceived Cognitive Impairment (PCI) score range 0-72 (The higher the score, the fewer cognitive complaints)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Months and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient diagnosed with localized breast cancer

  • Age 18 or older,

  • Who have received adjuvant or neo-adjuvant chemotherapy and are currently undergoing adjuvant radiotherapy (ongoing hormone therapy is permitted) until 30 days after end of radiotherapy.

  • Patients who report cognitive complaints that significantly impact their quality of life, as evaluated by the quality of life subscale of the FACT-Cog questionnaire. This subscale is composed by 4 questions:

  1. I have been upset about these problems;

  2. These problems have interfered with my ability to work;

  3. These problems have interfered with my ability to do things I enjoy;

  4. These problems have interfered with the quality of my life.

Patients are eligible if their score on this subscale is at or below the 10th percentile, based on age guidelines and normative data (Lange et al., 2015), namely:

  • ≤ 8 for patients aged 30-49 years

  • ≤ 9 for patients aged 50-69 years

  • ≤ 10 for patients aged 70-89 years

  • Patients who have completed at least three years of primary school education, as determined by the Barbizet scale,

  • Patient with access to a functional laptop/computer with a keyboard, internet connection and an e-mail account - being able to use those tools alone,

  • Fluent in French,

  • Patients who have provided informed consent to participate in the study.

Exclusion Criteria:
  • Personality disorder or any known progressive psychiatric pathology (e.g. schizophrenia),

  • Previous neurological history with ongoing cognitive symptoms (sequelae of head trauma, stroke, multiple sclerosis, epilepsy, neurodegenerative pathology, etc.),

  • Excessive alcohol intake or drug use, which could compromise participation to the intervention

  • Major visual and/or hearing deficit,

  • Patient who might not be able to complete neuropsychological testing, (including those with significant cognitive disorders that impede the completion of cognition tests, as determined by the cognitive screening test MoCA (MONTREAL COGNITIVE ASSESSMENT) and based on age and educational level according to GRECOGVASC (Reflection Group for Vascular COGnitive Assessment) normative data)

  • Already participating in a cognitive training program,

  • Refusal to participate,

  • Patient deprived of liberty or under guardianship,

  • Patient who might not be able to participate due to geographic, social or psychopathological reasons.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Polyclinique Bordeaux Nord Aquitaine Bordeaux France
2 Centre hospitalier de Bligny Briis-sous-Forges France
3 Centre François Baclesse Caen France 14000
4 Centre George François Leclerc Dijon France
5 Groupe Hospitalier Mutualiste de Grenoble Grenoble France
6 CHU de Limoges Limoges France
7 Centre Léon Bérard Lyon France
8 Institut Paoli Calmettes Marseille France
9 ICM Val d'Aurelle Montpellier France
10 Institut de Cancérologie de Lorraine Nancy France
11 Centre Antoine Lacassagne Nice France
12 CHU de Nimes Nimes France
13 La Pitié Salpétrière Paris France
14 Centre Arrmoricain d'Oncologie Plérin France
15 Centre Henri Becquerel Rouen France
16 Gustave Roussy Villejuif France

Sponsors and Collaborators

  • Centre Francois Baclesse
  • UNICANCER

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Francois Baclesse
ClinicalTrials.gov Identifier:
NCT06027632
Other Study ID Numbers:
  • 2023-A01134-41
First Posted:
Sep 7, 2023
Last Update Posted:
Sep 13, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 13, 2023